Company: EPR-PE
Filing Date: 2025-11-05
Form Type: 424B5
Source: 0001193125-25-266433
Chunk: 1

Company: EPR PROPERTIES
Filing Date: 2025-11-05
Form: 424B5
Chunk 1
---
 the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                  |     | Per note |        |   |     | Total |             |
|:---------------------------------|:----|:---------|-------:|:--|:----|:------|------------:|
| Public offering price(1)         |     |          | 98.800 | % |     | $     | 543,400,000 |
| Underwriting discount            |     |          |  0.600 | % |     | $     |   3,300,000 |
| Proceeds to us (before expenses) |     |          | 98.200 | % |     | $     | 540,100,000 |

| (1) | Plus accrued interest, if any, from November 13, 2025 if settlement occurs after that date. |

The notes will not be listed on any securities exchange or quoted on any automated dealer quotation system. There will be no public market for the notes. We expect that delivery of the notes will be made to purchasers through the book-entry delivery system of The Depository Trust Company and its participants, Clearstream Banking, S.A. and Euroclear Bank SA/NV, on or about November 13, 2025. Joint Book-Running Managers

| J.P. Morgan   |     | BofA Securities          |     | Barclays                     |     | RBC Capital Markets |
| Citigroup     |     | Citizens Capital Markets |     | KeyBanc Capital Markets      |     | Truist Securities   |
| Co-Managers   |     |                          |     |                              |     |                     |
| Raymond James |     | Stifel                   |     | UMB Financial Services, Inc. |     | US Bancorp          |

November 3, 2025

You should rely only on the information contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus and any free writing prospectus we may authorize to be delivered to you. Neither we nor the underwriters have authorized any person to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information